Each gastroresistant Depakine= tablet contains 200mg sodium valproate.
Each lOOm! Depaklnes syrup contains 5.764 gram sodium valproate.
Depakines is an antiepileptic drug, recommended for the treatment of various
types of epilepsy.
Patients with known hypersensitivity to the drug and patients with hepatic
If the patient experienced fatigue, drowsiness, loss of appetite associated with
repeated vomiting or recurrence of seizures, the physician should be contacted
Depakines treatment must be under regular medical supervision.
A pregnant patient, or planning to be, should notifYthe physician in order toprovide the specialized prenatal care. All drugs used concomitantly with Depakine” should be reported to the physician or to the pharmacist to avoid possible drug interactions. The syrup is initially intended for pediatric use and may be administered to adults only under physicians advice.
DepakiJiell may cause some un(lesrrable effec ,such as nausea,gastric pain
(at the beginning of treatment), increased appetite, liver or pancreatic disease,
transient hair loss, or slight tremor of the hands, these symptoms must be
reported to the physician.
Administration & Dosage;
– The average daily dose is 20-30mglkg body weight, divided into 2 or 3 doses
preferably taken with meals.
– T.hlp, •• honl<1 hp swallowed whole with water. hewed or broken.